Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Howard N, Bockbrader"'
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 46:395-404
Vixotrigine is a voltage and use dependent sodium channel blocker currently under development for treatment of various neuropathic pain indications. The objective of this work was to develop a population pharmacokinetic model and assess effects of va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fec4087251f61bf8e3a5bc55b4f579e
https://doi.org/10.1007/s13318-021-00678-0
https://doi.org/10.1007/s13318-021-00678-0
Publikováno v:
Journal of clinical pharmacologyReferences. 59(11)
A population pharmacokinetic (PK) model was developed to characterize the properties of pregabalin extended-release (ER) in healthy volunteers and was subsequently applied to patient data from efficacy/safety studies investigating pregabalin ER for p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f794e191e4cbdf18092de29bafcf70a
https://pubmed.ncbi.nlm.nih.gov/31183879
https://pubmed.ncbi.nlm.nih.gov/31183879
Autor:
Verne Pitman, Christine Alvey, Jing Liu, Elizabeth A Zegarac, John M. Pellock, Donald W. Mann, Howard N. Bockbrader, Marci L. Chew
Publikováno v:
Epilepsia. 55:1934-1943
To evaluate the safety, tolerability, and pharmacokinetics (PK) of pregabalin as adjunctive therapy in children with refractory partial seizures.This was a phase 1, randomized, placebo-controlled, parallel-group, escalating-dose, multiple-dose study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc3ecc91d53ca7e6270b61ecb5bcf8f3
https://doi.org/10.1111/epi.12830
https://doi.org/10.1111/epi.12830
Autor:
Verne Pitman, Christine Alvey, Joseph M. Scavone, Tanja Alebic-Kolbah, Howard N. Bockbrader, Marci L. Chew, Anna Plotka
Publikováno v:
Clinical Drug Investigation. 34:627-637
Pregabalin (Lyrica®) is approved as an immediate-release (IR) formulation for administration twice (BID) or three times (TID) a day depending on indication. Once daily (QD) dosing may be appropriate for ease of clinical use and patient convenience.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae2361dfacbe45d54d30f5b3e3836def
https://doi.org/10.1007/s40261-014-0221-2
https://doi.org/10.1007/s40261-014-0221-2
Publikováno v:
American Journal of Therapeutics. 20:32-36
The objective of this modeling study was to assess different dosage regimens that might be used to guide clinicians in transitioning patients from gabapentin to pregabalin therapy when such a transition is clinically warranted. Two different gabapent
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e707301a6786c95c62611aea700604b
https://doi.org/10.1097/mjt.0b013e318250f80e
https://doi.org/10.1097/mjt.0b013e318250f80e
Autor:
Howard N. Bockbrader, Marci L. Chew, Anna Plotka, Joseph M. Scavone, Christine Alvey, Verne Pitman, Tanja Alebic-Kolbah
Publikováno v:
Clinical drug investigation. 35(5)
The controlled-release (CR) formulation of pregabalin is designed to remain in the stomach for a prolonged period while slowly releasing pregabalin for absorption in the small intestine. This study evaluated the effect of the gastrointestinal prokine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c724ad60c2ca72aa730d00f2cac2aa29
https://pubmed.ncbi.nlm.nih.gov/25808394
https://pubmed.ncbi.nlm.nih.gov/25808394
Autor:
Christine Alvey, Howard N. Bockbrader, Marci L. Chew, Anna Plotka, Joseph M. Scavone, Tanja Alebic-Kolbah, Verne Pitman
Publikováno v:
Clinical drug investigation. 34(9)
The pharmacokinetic properties of the immediate-release (IR) and the recently developed controlled-release (CR) formulation of pregabalin are dose proportional. Pregabalin IR can be taken with or without food. This analysis characterizes the effect o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a14aa83bab1709c1a2727b75574f976e
https://pubmed.ncbi.nlm.nih.gov/25078976
https://pubmed.ncbi.nlm.nih.gov/25078976
Autor:
Daniele Ouellet, Samuel W. Boellner, David L. Wesche, Howard N. Bockbrader, Edward J. Randinitis, Richard R. Brown, Edward L. Posvar, George M. Haig
Publikováno v:
The Journal of Clinical Pharmacology. 41:507-514
Gabapentin (Neurontin) is a gamma-aminobutyric acid analogue indicated in adults for adjunctive treatment of partial seizures with or without secondary generalization. Two studies were conducted to determine the single-dose pharmacokinetics of gabape
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6bd6615a3c7d949517be6e304883c35
https://doi.org/10.1177/00912700122010384
https://doi.org/10.1177/00912700122010384
Autor:
Paul H. Siedlik, Jack Cook, Jeffrey R. Koup, Rebecca A. Boyd, Howard N. Bockbrader, Richard L. Lalonde, J. Robert Powell, Stephen C. Olson
Publikováno v:
Clinical Pharmacokinetics. 38:449-459
Continued scepticism about the benefits of population pharmacokinetics and/or population pharmacodynamics, here referred to collectively as the population approach, hampers its widespread application in drug development. At the same time the sources
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f358edccf54cc63665beea227887f705
https://doi.org/10.2165/00003088-200038050-00005
https://doi.org/10.2165/00003088-200038050-00005
Publikováno v:
Epilepsia. 40:474-479
Summary: Purpose: This study was conducted to evaluate the effect of age, age-related changes in renal function, and gender on the single-dose pharmacokinetics of orally administered gabapentin (GBP). Methods: The pharmacokinetics of a single 400-mg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85c41c9dff1fd570b38178b135a8b180
https://doi.org/10.1111/j.1528-1157.1999.tb00743.x
https://doi.org/10.1111/j.1528-1157.1999.tb00743.x